logo

IVVD

Invivyd
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About IVVD

Invivyd, Inc.

A biopharmaceutical company that develops antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and pre-emergent coronaviruses

Pharmaceutical
06/03/2020
08/06/2021
NASDAQ Stock Exchange
99
12-31
Common stock
1601 Trapelo Road, Suite 178, Waltham, MA 02451
--
Invivyd, Inc., was incorporated in Delaware on June 3, 2020. The company is a commercial-stage company with a mission to rapidly and permanently deliver antibody-based therapies to protect vulnerable populations from the devastating consequences of the pandemic virus threat, starting with SARS-CoV-2. The company's proprietary INVYMAB platform approach combines state-of-the-art virus surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid and continuous generation of new monoclonal antibodies (" MABs ") to keep pace with the evolving viral threat.

Company Financials

EPS

IVVD has released its 2024 Q4 earnings. EPS was reported at -0.15, versus the expected -0.10, missing expectations. The chart below visualizes how IVVD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IVVD has released its 2024 Q4 earnings report, with revenue of 13.82M, reflecting a YoY change of NaN%, and net profit of -18.44M, showing a YoY change of 74.96%. The Sankey diagram below clearly presents IVVD’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime